Varian gains more worldwide sites for RapidArc system
Varian gains more worldwide sites for RapidArc system
Varian Medical Systems has placed its RapidArc Radiotherapy unit at the following institutions:
• Bern University Hospital in Bern, Switzerland
• Chang Gung Memorial Hospital in Linkou, Taiwan
• Gottingen University Hospital in Gottingen, Germany
• Innovative Cancer Institute in S. Miami, Fla.
• Lehigh Valley Health Network in Allentown and Bethlehem, Penn.
• New Mexico Cancer Center in Albuquerque
• Northwoods Cancer Center in Woodlands, Tex.
• Pamela Youde Nethersole Eastern Hospital in Hong Kong
• Sudharz Krankenhaus in Nordhausen, Germany
• Trinitas Comprehensive Cancer Center in Elizabeth, N.J.
• Zurich University Hospital
Articles in this issue
Drug with tumor-specific target fells cancerous B cells while sparing healthy ones in NHL
Expanded Medicare coverage of PET draws kudos from oncology community
Who's News
Push for comparative effectiveness research
Should lymphadenectomy be the standard of care in melanoma metastasis to the sentinel lymph nodes?
Lack of persuasive data continues to plague PSA testing
Aggressive colon cancer treatment: A matter of tolerability vs necessity
Less toxic protocol proves efficacious in chronic lymphocytic leukemia pts
ASCO draws road map to navigate economic, racial disparities in ca care
Clinical trials flourish in international setting
Global lung ca staging lexicon undergoes major overhaul
Decision-analytic model aids cervical cancer treatment
Elekta pledges $1 million to support RT research
Varian gains more worldwide sites for RapidArc system
Focus on Lung Cancer
Recent Videos
Related Content
![TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fbb58c5f3c3692dc35c19320bb63c3df864f9b79b-1500x722.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC")
